Aura Biosciences, Inc. (AURA)

$9.25

Live

Insights on Aura Biosciences, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 326.7%

Performance

  • $9.25
    $9.67
    $9.25
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.32%

    Upside

    4.32%

    downward going graph
  • $8.13
    $19.18
    $9.25
    downward going graph

    12.11%

    Downside

    52 Weeks Volatility :57.61%

    Upside

    51.77%

    downward going graph

Returns

PeriodAura Biosciences, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-20.19%
-1.4%
0.0%
6 Months
3.93%
2.2%
2.0%
1 Year
-36.82%
6.0%
5.3%
3 Years
-37.5%
26.3%
19.9%

Highlights

Market Capitalization
398.8M
Book Value
$4.37
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.98
Wall Street Target Price
27.4
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.99%
Return On Equity TTM
-46.17%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-72.1M
Diluted Eps TTM
-1.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.01
EPS Estimate Next Year
-2.38
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.51

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Aura Biosciences, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 196.22%

Current $9.25
Target $27.40

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aura Biosciences, Inc.
Aura Biosciences, Inc.
-9.93%
3.93%
-36.82%
-37.5%
-37.5%
Moderna, Inc.
Moderna, Inc.
-10.67%
-32.6%
-16.46%
43.93%
437.58%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.66%
0.54%
20.22%
43.69%
111.47%
Novo Nordisk A/s
Novo Nordisk A/s
2.15%
146.19%
299.73%
451.49%
690.33%
Seagen, Inc.
Seagen, Inc.
6.95%
7.06%
57.98%
15.54%
167.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.15%
13.31%
26.28%
30.33%
91.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aura Biosciences, Inc.
Aura Biosciences, Inc.
NA
NA
NA
-2.01
-0.46
-0.28
0.0
4.37
Moderna, Inc.
Moderna, Inc.
34.92
34.92
0.0
-3.42
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.9
21.9
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.86
42.86
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.48
27.48
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aura Biosciences, Inc.
Aura Biosciences, Inc.
Buy
$398.8M
-37.5%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.1B
437.58%
34.92
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$89.4B
111.47%
21.9
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$409.3B
690.33%
42.86
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.7B
167.56%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
91.37%
27.48
35.4%

Institutional Holdings

  • Matrix Capital Management Company, LLC

    14.04%
  • Medicxi Ventures Management (Jersey) Ltd

    7.96%
  • Eventide Asset Management, LLC

    7.69%
  • Adage Capital Partners Gp LLC

    7.09%
  • Citadel Advisors Llc

    6.44%
  • BlackRock Inc

    4.90%

Corporate Announcements

  • Aura Biosciences, Inc. Earnings

    Aura Biosciences, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo

Organization
Aura Biosciences, Inc.
Employees
70
CEO
Dr. Elisabet de los Pinos Ph.D.
Industry
Healthcare

FAQs